Since several pre-clinical studies have shown the anti-inflammatory properties of OxA not only in models of IBD, but also in other chronic/acute inflammatory diseases, such as multiple sclerosis [13] and septic shock [14], it urges further studies to reinforce the view that the OxA/OX1R system may represent a promising new target in the treatment of UC. Here, HCRTR1 is linked to inflammatory bowel disease.